AWE
GILD icon

Avidian Wealth Enterprises’s Gilead Sciences GILD Stock Holding History

Avidian Wealth Enterprises’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.84M Buy
14,589
+727
+5% +$95.8K 0.05% 227
2026
Q1 		$1.93M Buy
13,862
+2,808
+25% +$393K 0.06% 198
2025
Q4 		$1.36M Buy
11,054
+500
+5% +$60.8K 0.05% 182
2025
Q3 		$1.17M Buy
10,554
+510
+5% +$58K 0.04% 198
2025
Q2 		$1.11M Buy
10,044
+367
+4% +$39.1K 0.05% 192
2025
Q1 		$1.08M Buy
9,677
+504
+5% +$52K 0.05% 185
2024
Q4 		$847K Buy
9,173
+561
+7% +$50.5K 0.04% 211
2024
Q3 		$722K Buy
8,612
+310
+4% +$23.7K 0.03% 237
2024
Q2 		$570K Buy
8,302
+1,561
+23% +$104K 0.02% 265
2024
Q1 		$494K Sell
6,741
-1,407
-17% -$108K 0.02% 267
2023
Q4 		$660K Buy
8,148
+259
+3% +$20.2K 0.04% 215
2023
Q3 		$591K Sell
7,889
-204
-3% -$15.7K 0.04% 227
2023
Q2 		$624K Sell
8,093
-1,875
-19% -$150K 0.04% 238
2023
Q1 		$827K Sell
9,968
-8
-0.1% -$663 0.05% 224
2022
Q4 		$856K Buy
9,976
+417
+4% +$33K 0.06% 199
2022
Q3 		$590K Sell
9,559
-1,549
-14% -$97.7K 0.04% 213
2022
Q2 		$687K Buy
11,108
+1,142
+11% +$70.7K 0.05% 219
2022
Q1 		$593K Buy
9,966
+707
+8% +$45.2K 0.04% 270
2021
Q4 		$672K Buy
9,259
+15
+0.2% +$1.03K 0.04% 250
2021
Q3 		$646K Buy
9,244
+631
+7% +$44.3K 0.05% 184
2021
Q2 		$593K Sell
8,613
-137
-2% -$9.15K 0.05% 189
2021
Q1 		$566K Sell
8,750
-701
-7% -$45.2K 0.05% 188
2020
Q4 		$551K Buy
9,451
+425
+5% +$25.6K 0.05% 169
2020
Q3 		$570K Buy
9,026
+3,299
+58% +$229K 0.06% 142
2020
Q2 		$441K Buy
5,727
+1,199
+26% +$91.9K 0.06% 147
2020
Q1 		$339K Buy
4,528
+21
+0.5% +$1.45K 0.05% 135
2019
Q4 		$293K Sell
4,507
-3
-0.1% -$195 0.04% 181
2019
Q3 		$286K Buy
4,510
+304
+7% +$19.9K 0.05% 153
2019
Q2 		$284K Buy
4,206
+1,025
+32% +$67.4K 0.07% 114
2019
Q1 		$207K Buy
+3,181
New +$211K 0.05% 125

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Avidian Wealth Enterprises's GILD Position: Q2 2026 in Review

Avidian Wealth Enterprises increased its Gilead Sciences (GILD) stake by 5.2% in Q2 2026, buying an estimated $95.8K and bringing the position to 14,589 shares worth $1.84M. The position accounts for 0.05% of the portfolio, ranked #227.

Avidian Wealth Enterprises first reported a position in GILD in Q1 2019 and has held it in 30 quarters since. The position peaked at $1.93M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Avidian Wealth Enterprises held 14,589 shares of Gilead Sciences worth $1.84M as of Q2 2026.
  • Avidian Wealth Enterprises bought 727 Gilead Sciences shares in Q2 2026, an estimated $95.8K.
  • Gilead Sciences made up 0.05% of Avidian Wealth Enterprises's portfolio in Q2 2026, its #227 holding.
  • Avidian Wealth Enterprises first reported a position in Gilead Sciences in Q1 2019 and has held it in 30 quarters since.
  • Avidian Wealth Enterprises's Gilead Sciences position peaked at $1.93M in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Avidian Wealth Enterprises's 13F filing for Q2 2026, filed 24 Jul 2026.